Smart Contact Lenses for IOP Monitoring: August 2026 Clinical Utility Results

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/smart-contact-lenses-for-iop-monitoring-august-2026-clinical-utility-resultsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Smart Contact Lenses for Intraocular Pressure Monitoring: August 2026 Clinical Utility Results Evidence reviewed through August 18, 2026. Introduction Smart contact lenses and other wearable sensors aim to solve a major problem in glaucoma care: eye pressure is measured only occasionally in most clinics, even though it changes throughout the day and may rise during sleep or while lying down. The August 2026 evidence is promising but more limited than some headlines suggest. The newest soft contact lens studies show that overnight and closed-eye monitoring is technically feasible. However, there is still no large, peer-reviewed clinical trial showing that an external smart contact lens improves vision, slows glaucoma progression, or reliably changes treatment based on automated alerts. The strongest real-world evidence for remote treatment decisions comes from implantable telemetric sensors and, to a lesser degree, home rebound tonometry rather than from external smart contact lenses. Nocturnal soft contact lens study Ongoing smart contact lens trial Implantable sensor progression study Executive Summary New soft contact lens technology: The 2026 nocturnal sensor demonstrated closed-eye and recumbent monitoring in a very small human pilot involving a healthy participant and a participant with pigmentary glaucoma. It reported encouraging comfort and signal stability, but no cohort-level adherence, data-completeness, treatment-change, or vision-outcome results. Advanced Materials report Triggerfish: The commercially available SENSIMED Triggerfish detects changes in ocular dimensions related to pressure, rather than directly reporting pressure in millimeters of mercury. It can identify the likely timing of pressure peaks, but its United States authorization limits clinical use to helping identify when conventional pressure measurement should be performed. United States Food and Drug Administration United States Food and Drug Administration review Implantable EyeMate sensors: These devices provide the most mature continuous telemetric data. In one remote-monitoring study, data led to treatment changes in 5 of 34 patients who submitted measurements, while treatment changes were considered in another 5 patients. Remote telemetric monitoring study Home tonometry: iCare HOME2 offers a more practical alternative for intermittent home measurements. In a 75-patient prospective cohort, 65% obtained at least six measurements per day, while 19% obtained fewer than two per day. The device identified maximum pressure outside clinic hours in 36% of patients. Home tonometry cohort Payer position: Publicly available 2026 policies from Aetna and Anthem classify continuous pressure monitoring and home tonometry as investigational, unproven, or not medically necessary for routine glaucoma care. Aetna policy Anthem policy What the Devices Actually Measure External smart contact lenses There are two broad approaches: Relative-signal sensors, such as Triggerfish, detect changes in corneal or corneoscleral shape that are believed to reflect pressure changes. Quantitative sensors, such as the newer Purdue-developed soft lenses, attempt to convert mechanical deformation into an absolute pressure estimate in millimeters of mercury. This distinction is clinically important. A relative signal may show that a patient’s pressure-related ocular changes increased overnight, but it does not necessarily mean that a reading of “higher” corresponds to a specific pressure such as 25 millimeters of mercury. Calibration can vary with lens fit, corneal curvature, corneal thickness, posture, eyelid position, and individual ocular biomechanics. NICE technology review Triggerfish clinical review Implantable telemetric sensors EyeMate sensors are implanted inside the eye and are read by an external handheld or wearable reader. Unlike Triggerfish, the implant is designed to measure actual intraocular pressure rather than only an indirect dimensional signal. The disadvantage is that implantation requires intraocular surgery, generally at the time of glaucoma or cataract surgery. EyeMate-SC trial EyeMate-IO trial Home rebound tonometry The iCare HOME and iCare HOME2 devices do not continuously monitor pressure. Instead, the patient takes individual measurements at selected times, often several times per day. This makes them less passive than a contact lens but substantially easier to validate, replace, and interpret against Goldmann applanation tonometry. August 2026 Contact Lens Evidence 2026 nocturnal soft contact lens The newest peer-reviewed study, published online in June 2026, evaluated a soft contact lens with an embedded wireless pressure sensor and a reader integrated into a sleep mask. The design specifically addressed two limitations of earlier devices: closed-eye operation and stable sensing while lying down. Nocturnal intraocular pressure monitoring study The study demonstrated: Stable sensing with the eye open and closed. Monitoring during sitting and recumbent postures. Resistance to moderate eye and head movement. Ex vivo sensitivity of approximately 0.163 megahertz per millimeter of mercury, with a calibration coefficient of R² = 0.977. Human testing in a healthy participant and a participant with pigmentary glaucoma. Comfort ratings generally above 90 on the study’s 0–100 comfort scale after transition to a recumbent, eyes-closed posture. No meaningful subjective visual distortion, although mild regional visual-field reductions were observed in testing and remained within functional limits. Advanced Materials full report What the 2026 study did not show The study did not establish: Agreement with Goldmann applanation tonometry in a clinical cohort. A validated conversion equation applicable across patients. Overnight wear adherence in a larger population. The percentage of usable or missing data during sleep. The sensitivity or specificity of automated alerts. Treatment changes caused by sensor readings. Reduced visual-field loss or slower glaucoma progression. Therefore, it should be regarded as a human feasibility and engineering-validation study, not as a clinical utility trial. Earlier smart soft contact lens data A 2022 Nature Communications study evaluated a different soft contact lens design in three adult contact-lens users. One participant had mild ocular hypertension. The lens produced a pressure-related signal that correlated with reference measurements across different postures, with a reported calibration fit of R² = 0.91. Its readings agreed more closely with the iCare Home device and Goldmann applanation tonometry than did the Triggerfish signal in the same testing environment. Smart soft contact lens study Comfort was favorable compared with Triggerfish, although the comparison used only three participants: Smart soft lens after adaptation: 12.7 ± 5.4 on a scale where lower scores indicated less discomfort. Bare soft contact lens: 4.0 ± 4.2. Triggerfish insertion: 46.7 ± 30.1. Triggerfish removal: 68.3 ± 6.2. The authors demonstrated 24-hour monitoring in a dog, but the human component involved short-term, in-clinic testing rather than overnight human monitoring. No adherence, data-completeness, management-change, or glaucoma-progression data were reported. Smart soft contact lens study A United States clinical trial of smart soft contact lenses began in October 2025 and is planned to enroll approximately 120 participants, with estimated completion in September 2028. As of August 18, 2026, the trial registry did not show mature clinical utility results. ClinicalTrials.gov study record Correlation With Goldmann Applanation Tonometry Triggerfish: useful for timing, not interchangeable pressure values Triggerfish does not directly provide a conventional pressure value in millimeters of mercury. Its output is an electrical signal representing changes in ocular dimensions. The United States Food and Drug Administration authorized it to identify the likely time window of peak pressure so that a clinician can perform conventional measurement at a more informative time. The regulatory review specifically states that treatment and diagnostic decisions should continue to rely on traditional clinical methods. United States Food and Drug Administration United States Food and Drug Administration review In a repeated 24-hour study of 40 glaucoma suspects and glaucoma patients: Blurred vision occurred in 82.5%. Conjunctival redness occurred in 80.0%. Superficial punctate keratitis occurred in 15.0%. Mean discomfort scores were approximately 27 and 24 on a 0–100 scale during two sessions. The correlation between repeated pressure-related profiles was approximately 0.59, indicating fair reproducibility rather than highly precise repeatability. Triggerfish safety and reproducibility study The central limitation is that a reproducible relative pattern is not the same as an accurate absolute pressure measurement. Lens position, corneal shape, and pressure-independent changes in ocular biomechanics can influence the signal. New quantitative lenses The newer soft lenses are designed to generate absolute pressure estimates. The available human evidence is encouraging, but the numbers come from very small studies. The 2022 human stuSupport the show